Third Wave Technologies, Inc.

Eragen Biosciences, Inc.

Luminex Corporation

Centrose, LLC

James Robert Prudent

Victor I Lyamichev

James E Dahlberg

David J Marshall

Jeff G Hall

Mary Ann D Brow

Christopher B Sherrill

Jerod L Ptacin

Jennifer K Grenier

Craig S Richmond

Bruce P Neri

Mary Ann Brow

Fang Dong

Lance Fors

Christopher W Scherrer

Gideon Shapiro

Simona Jurczyk

Charles R Hutchinson

Todd A Anderson

Michael James Moser

David Michael Olive

Hatim T Allawi

Sarah R Wayland

Scott C Johnson

Michael W Kaiser

Eric B Roesch

Zbigniev Skrzypczynski

Tsetska Y Takova

Jon S Thorson

Mohammed Saleh Shekhani

Christine A Larsen

Jeff Steven Hall

Brian Aizenstein

Andrea L Mast

Poonam Agarwal

Scott M Law

Natasha Lyamicheva

Eric B Rasmussen

David Arco

Myrta W Atiles

Deborah E Burris

Monika De Arruda Indig

Cristopher V Van Hout

Carolyn W Miller

Mary C Oldenberg

Jennifer M Schneiders

Jeff Steven Grotelueschen Hall

James L Dahlberg

Christopher V Van Hout

Simon Jurczyk

Charles B Hutchinson

Jill Hutchinson Bollettieri

Natascha Lyamicheva

Jeff G Grotlueschen Hall

Christopher B Scherrill

Extracellular drug conjugates (EDCs) targeting CD38 are useful in the treatment of diseases such as cancer and immune disorders, including asthma.

Extracellular targeted drug conjugates

Solid support assays using non-standard bases are described. A capture oligonucleotide comprising a molecular recognition sequence is attached to a solid support and hybridized with a target. In some instances, the molecular recognition sequence includes one or more non-standard bases and hybridizes to a complementary tagging sequence of the target oligonucleotide. In other instances, incorporation of a non-standard base (e.g., via PCR or ligation) is used in the assay.

Solid support assay systems and methods utilizing non-standard bases

Assays using non-natural bases are described. In one embodiment, the method involves contacting a sample suspected of containing the target nucleic acid with a polymerase and first and second primers; amplifying the target nucleic acid by PCR using the first and second primers to generate an amplification product having a double-stranded region and a single-stranded region that comprises the non-natural base; contacting the sample with a reporter comprising a label and a non-natural base that is complementary to the non-natural base of the single-stranded region; annealing at least a portion of the reporter to the single-stranded region of the amplification product; and correlating a signal of the label with the presence of the target nucleic acid in the sample. The invention also provides corresponding kits for use in detecting target nucleic acids in a sample.

Materials and methods for detection of nucleic acids

The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.

The present invention provides glycoside compounds, methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and a method for the treatment of hyperproliferative diseases using the same.

Glycoside compounds and pharmaceutical compositions thereof

The present invention provides nucleic acid based polymerase inhibitors and methods for reducing non-specific polymerase extension and amplification in nucleic acid amplification reactions. The polymerase inhibitors provide a double stranded nucleic acid portion that is recognized by a polymerase enzyme as a template for extension but is incapable of being extended by the polymerase enzyme. The polymerase binds to the polymerase inhibitor which sequesters the enzyme until the temperature achieves a level that denatures the double stranded portion of the inhibitor after which the polymerase is released and can then catalyze nucleic acid extension.

Polymerase inhibitor and method of using same

Solid support assays using non-standard bases are described. A capture oligonucleotide comprising a molecular recognition sequence is attached to a solid support and hybridized with a target oligonucleotide. In some instances, the molecular recognition sequence includes one or more non-standard bases and hybridizes to a complementary tagging sequence of the target oligonucleotide. In other instances, incorporation of a non-standard base (e.g., via PCR or ligation) is used in the assay.

The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.

Cleavage of nucleic acids

The present invention relates to methods and compositions for analyzing nucleic acids. In particular, the present invention provides methods and compositions for the detection and characterization of nucleic acid sequences and sequence changes. The methods of the present invention permit the detection and/or identification of genetic polymorphism such as those associated with human disease and permit the identification of pathogens (e.g., viral and bacterial strain identification).

Methods for analyzing nucleic acid

Growing community of inventors

Madison, WI, United States of America

James Robert Prudent